Immunological Phenotype and Prognosis of T-Lineage Malignancy in Children

• Published in: The Japanese Journal of Pediatric Hematology Vol. 7; no. 1; pp. 41 - 46
• Main Authors: INOUE, Masami, HARA, Junichi, SAKATA, Naoki, TAWA, Akio, KAW-HA, Keisei, ISHIHARA, Shigehiko, OSUGI, Yuko, KOUDERA, Urara, KURAHASHI, Hiroki, YUMURA-YAGI, Keiko, KONISHI, Syouzaburou, SAKO, Masanori
• Format: Journal Article
• Language: Japanese
• Published: THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY 1993; 特定非営利活動法人 日本小児血液・がん学会
• Subjects: HDCA; phenotype; T-lineage ALL/NHL
• ISSN: 0913-8706; 1884-4723
• DOI: 10.11412/jjph1987.7.41

The efficacy of high-dose cytosine arabinoside (HDCA) and phenotypic difference in the prognosis were investigated in T-lineage malignancies (ALL and NHL) in children. Twenty-nine patients from July 1984 to December 1991 were included in this study. Ten patients were treated with the regimen without HDCA (Group A), 9 received single HDCA intensification (Group B) and 10 were treated with cyclic HDCA intensifications (Group C). Disease-free survival (DFS) rates at 48 months were 48%, 38.1% and 71%, respectively. Although these values were not significantly different, cyclic HDCA intensifications seem to be effective for T-ALL and NHL in children, because only 2 patients of Group C relapsed. The phenotype of the samples from Group B and C was divided into 3 groups, i.e., CD3 + group; CD3-, CD4+ and/or CD8+group; and CD3-, CD4-and CD8-group. The patients whose leukemic cells expressed CD3 had a favorable prognosis, and the patients with CD3-, CD4-and CD8-had the worst. Further study is needed to clarify whether the phenotype remains a prognostic factor in patients treated with very intensive therapies or not.